Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics (VIRX)
NASDAQ:VIRX
Viracta Therapeutics (VIRX) Stock Price & Analysis
816 Followers
VIRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.43 - $2.38
Previous Close$0.86
Volume52.62K
Average Volume (3M)115.64K
Market Cap
$35.70M
Enterprise Value-$1.69M
Total Cash (Recent Filing)$62.95M
Total Debt (Recent Filing)$25.56M
Price to Earnings (P/E)-0.6
Beta0.90
Next Earnings
May 07, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding39,272,434
10 Day Avg. Volume218,471
30 Day Avg. Volume115,636
Standard Deviation0.30
R-Squared0.00375
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$7.67Price Target Upside795.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Viracta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsClinical trial results show nana-val achieving meaningful response rates compared to competitors.
Financial HealthViracta has sufficient cash reserves to provide an operational runway into the following year.
Regulatory MilestoneUpcoming catalysts announced, including several data readouts and discussions with the FDA for accelerated approval.
Bears Say
Clinical Trial ResultsA Nstat monotherapy cohort, required by the FDA, showed limited efficacy with only a 10% overall response rate in treated patients.
Drug Efficacy And Market CompetitionRisks include potential inability to generate further favorable clinical data, failure to secure accelerated FDA approval, and possible poorer market uptake due to competition or other factors.
Drug Safety ConcernsInvestor concerns arose due to a serious adverse event related to the drug that resulted in a patient's death from pancytopenia and sepsis.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VIRX FAQ
What was Viracta Therapeutics’s price range in the past 12 months?
Viracta Therapeutics lowest stock price was $0.43 and its highest was $2.38 in the past 12 months.
What is Viracta Therapeutics’s market cap?
Currently, no data Available
When is Viracta Therapeutics’s upcoming earnings report date?
Viracta Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 16 days.
How were Viracta Therapeutics’s earnings last quarter?
Viracta Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.04.
Is Viracta Therapeutics overvalued?
According to Wall Street analysts Viracta Therapeutics’s price is currently Undervalued.
Does Viracta Therapeutics pay dividends?
Viracta Therapeutics does not currently pay dividends.
What is Viracta Therapeutics’s EPS estimate?
Viracta Therapeutics’s EPS estimate is -$0.35.
How many shares outstanding does Viracta Therapeutics have?
Viracta Therapeutics has 39,272,434 shares outstanding.
What happened to Viracta Therapeutics’s price movement after its last earnings report?
Viracta Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 4.938%.
Which hedge fund is a major shareholder of Viracta Therapeutics?
Among the largest hedge funds holding Viracta Therapeutics’s share is Aisling Capital Management LP. It holds Viracta Therapeutics’s shares valued at 164K.
---
Viracta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (795.30% Upside)
$7.67 (795.30% Upside)
Blogger Sentiment
Bullish
VIRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.67%
12-Months-Change
Fundamentals
Return on Equity
-128.34%
Trailing 12-Months
Asset Growth
-40.94%
Trailing 12-Months
Company Description
Viracta Therapeutics
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
---
VIRX Stock 12 Months Forecast
Average Price Target
$7.67
▲(795.30% Upside)
Technical Analysis
Best Analysts Covering VIRX
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-34.73%
reiterated a buy rating 7 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -34.73% per trade.
---